LNP
Lipid nanoparticles (LNPs) are one of the most widely used delivery systems for nucleic acid therapeutics, including mRNA, siRNA, and gene-editing cargos. LNP formulations typically consist of ionizable lipids, phospholipids, cholesterol, and PEG-lipids that self-assemble into nanoscale particles capable of encapsulating fragile nucleic acids. Ionizable lipids remain neutral in circulation but become positively charged in acidic endosomal environments, facilitating membrane fusion and endosomal escape. This mechanism enables efficient cytoplasmic delivery of nucleic acids while protecting them from degradation during systemic circulation.
LNP technology provides a scalable and clinically validated platform for nucleic acid therapeutics. Its modular design enables optimization of delivery efficiency, tissue targeting, and safety profiles through lipid composition engineering. Today, LNPs are widely used in mRNA vaccines, RNA interference therapeutics, and emerging gene-editing applications. Continuous advances in lipid chemistry and nanoparticle formulation are enabling next-generation delivery systems with improved tissue selectivity and enhanced therapeutic performance.
